Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zuberitamab as First-Line Preemptive Therapy for EBV Infection Post-HSCT
NCT07261215Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2026
- Primary completion
- Oct 2026
- Modality
- IgG Antibodies
01
Overview
Phase 2, open-label, single-arm trial of hlx01 in Epstein-Barr virus infection, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Epstein-Barr Virus DNA clearance rate at 28 days. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
hlx01
03
Conditions
Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT07261215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07261215.